25
February 2025
Aptamer Group
plc
("Aptamer", the "Company" or the "Group")
Notice of Results and
Investor Presentation
Aptamer Group plc (AIM: APTA), the
developer of novel Optimer® binders to enable innovation in
the life sciences industry, will announce its interim results for
the six months ended 31 December 2024 on Tuesday, 11 March
2025.
The Company is pleased to announce
that Dr Arron Tolley, Chief Executive Officer and Andrew Rapson,
Chief Financial Officer, will provide a live presentation relating
to the interim results via Investor Meet Company on Tuesday, 11
March 2025, at 14:00 GMT.
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until Monday,
10 March 2025, 09:00 GMT, or at any time during the live
presentation.
Investors can sign up to Investor
Meet Company for free and add to meet Aptamer Group plc
via:
https://www.investormeetcompany.com/aptamer-group-plc/register-investor
Investors who already follow Aptamer
Group plc on the Investor Meet Company platform will automatically
be invited.
- Ends -
For
further information, please contact:
|
Aptamer Group plc
Arron Tolley, Chief Executive
Officer
|
+44 (0) 1904 217
404
|
|
SPARK Advisory Partners Limited - Nominated
Adviser
Andrew Emmott / Jade
Bayat
|
+44 (0) 20 3368
3550
|
|
Turner Pope Investments (TPI) Limited -
Broker
James Pope / Andrew
Thacker
|
+44 (0) 20 3657
0050
|
|
Northstar Communications Limited - Investor
Relations
Sarah Hollins
|
+44 (0) 113 730 3896
|
About Aptamer Group plc
Aptamer Group is a leading global
developer of aptamer-based ligands that help scientists remove the
limits to discovery and innovation. Leveraging several proprietary
discovery and development platform, Aptamer delivers custom
affinity ligands, supported with a complete suite of
characterisation and validatory assays that enhance the translation
of its binders and optimise scientific outcomes for
customers.
Aptamer's cutting-edge technology
spans healthcare, research, personal care, and industrial
processes, delivering new affinity solutions for novel targets,
advanced diagnostics, and precision therapies. By working with
industry leaders in pharmaceutical, biotechnology, personal health,
academic, and clinical research sectors, Aptamer is accelerating
science through the custom development of tools and
therapies.
To register for news alerts by email
go to https://aptamergroup.com/investors/investor-news-email-alerts/
